The Nuclear Receptor ROR Gamma pipeline drugs market research report outlays comprehensive information on the Nuclear Receptor ROR Gamma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Nuclear Receptor ROR Gamma pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Gastrointestinal, Musculoskeletal Disorders, and Oncology which include the indications Psoriasis, Autoimmune Disorders, Ulcerative Colitis, Inflammatory Bowel Disease, Fibrosis, Psoriatic Arthritis, Oncology, and Breast Cancer. It also reviews key players involved in Nuclear Receptor ROR Gamma targeted therapeutics development with respective active and dormant or discontinued products.
The Nuclear Receptor ROR Gamma pipeline targets constitutes close to 24 molecules. Out of which, approximately 22 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 4, 4, 11, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Nuclear Receptor ROR Gamma overview
RAR-related orphan receptor gamma (RORγ) is a protein encoded by the RORC gene. RORγ is member of the nuclear receptor family of transcription factors. It exist in two isoforms RORγ and RORγt. RORγ is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R ORγt, appears to be highly restricted to the thymus. RORγ isoform is involved in the regulation of circadian rhythms and RORγt plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.
For a complete picture of Nuclear Receptor ROR Gamma’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
